Pacific Biosciences of California, Inc. (PACB)
| Market Cap | 1.17B |
| Revenue (ttm) | 134.69M |
| Net Income (ttm) | -175.29M |
| Shares Out | 224.38M |
| EPS (ttm) | -0.89 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,907,692 |
| Open | 5.53 |
| Previous Close | 5.73 |
| Day's Range | 5.16 - 5.75 |
| 52-Week Range | 4.51 - 36.36 |
| Beta | 1.26 |
| Analysts | Buy |
| Price Target | 17.95 (+243.9%) |
| Earnings Date | May 4, 2022 |
About PACB
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonuclease...
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for PACB stock is "Buy." The 12-month stock price forecast is 17.95, which is an increase of 243.87% from the latest price.
News
PacBio Collaborates with iLAC and Robotic Biology Institute to Develop Automated Workflows
Advanced Automation Aims to Optimize Service Lab Efficiency and Highly Reproducible Data Production from HiFi Long-Read Sequencing Advanced Automation Aims to Optimize Service Lab Efficiency and Highly ...
PacBio to Participate in the BofA Securities 2022 Healthcare Conference
MENLO PARK, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- PacBio announced today that it will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada.
PacBio's (PACB) Q1 Earnings Miss Estimates, Revenues Beat
PacBio (PACB) sees strength in Q1 segmental revenues, led by robust consumable and instrument sales.
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -15.63% and 1.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
PacBio Announces First Quarter 2022 Financial Results
MENLO PARK, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2022.
Pacific Biosciences of California (PACB) Expected to Beat Earnings Estimates: Should You Buy?
Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PacBio and Children's Mercy Kansas City Expand Collaboration Taking a Multi-Omics Approach to Characterize Rare Disease
MENLO PARK, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced an expanded research collaboration...
PacBio transforms access to the epigenome and streamlines workflows
Significant enhancements to the Sequel II/IIe platform include methylation calling in native DNA, greatly accelerated sample preparation, and support for gene therapy applications Significant enhancemen...
PacBio to Report First Quarter 2022 Financial Results on May 4, 2022
MENLO PARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2022 financial results on Wednes...
3 Things About Pacific Biosciences of California That Smart Investors Know
Anyone thinking about buying shares should know them, too.
PacBio Enters Agricultural Industry Collaboration with Corteva Agriscience to Develop High-Throughput Plant, Pest and...
The companies will leverage high-throughput whole genome HiFi sequencing for advanced plant biotechnology, breeding and crop protection product development The companies will leverage high-throughput wh...
HiFi Reads Enable Telomere-to-Telomere Consortium to Fill the Final Gaps in the Human Genome, Heralding a New Era of ...
Science magazine publication details how the human genome was finally completed with the help of PacBio long-read technology Science magazine publication details how the human genome was finally complet...
PacBio Opens European Headquarters in London
Company Announces New European Headquarters to Serve Growing Customer Demand in Europe, Middle East and Africa Region
Why Is Pacific Biosciences (PACB) Down 13.6% Since Last Earnings Report?
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock?
PacBio (PACB) Supports SickKids With Sequencing Technology
PacBio (PACB) to help SickKids in detecting potential genetic causes of a range of medical and developmental conditions.
PacBio Supports SickKids to Investigate Use of HiFi Sequencing in Undiagnosed Genetic Conditions
SickKids will use HiFi Sequencing to explore potential genetic causes of a range of medical and developmental conditions SickKids will use HiFi Sequencing to explore potential genetic causes of a range ...
PacBio Grants Equity Incentive Award to New Employee
MENLO PARK, Calif., Feb. 25, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of ...
PacBio Welcomes Dr. Michael Eberle as Vice President of Computational Biology
Genomics Industry Veteran to Oversee Development of Robust Computational Biology Program Genomics Industry Veteran to Oversee Development of Robust Computational Biology Program
PacBio's (PACB) Q4 Earnings Miss Estimates, Revenues Top
PacBio (PACB) sees strength in Q4 segmental revenues, led by robust consumable and instrument sales.
KK Women's and Children's Hospital and PacBio Collaborate in Asia's First Study of Unexplained Neurodevelopmental Dis...
PacBio HiFi Sequencing Technology Will Be Used to Investigate Effect on Diagnostic Yield of Unresolved Rare Diseases in Children PacBio HiFi Sequencing Technology Will Be Used to Investigate Effect on D...
Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -7.14% and 0.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
PacBio Announces Fourth Quarter and Fiscal Year 2021 Financial Results
MENLO PARK, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2021.
PacBio to Present at Upcoming Investor Conferences
MENLO PARK, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- PacBio announced today that its executives will be speaking virtually at the following investor conferences:
Analysts Estimate Pacific Biosciences of California (PACB) to Report a Decline in Earnings: What to Look Out for
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PacBio to Report Fourth Quarter and Full Year 2021 Financial Results on February 15, 2022
MENLO PARK, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2021 financial res...